Home > Boards > US Listed > Medical - Drugs > Relmada Therapeutics Inc. (RLMD)

NEWS -- Relmada Therapeutics to Participate in Upcoming

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Paulness Member Profile
 
Followed By 75
Posts 10,617
Boards Moderated 0
Alias Born 11/02/03
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/5/2021 4:09:28 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 3/31/2021 5:02:19 PM
Relmada Therapeutics EPS misses by $0.25 Seeking Alpha - 3/23/2021 4:31:48 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/15/2021 5:17:15 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/15/2021 5:14:39 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/11/2021 5:52:09 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/11/2021 5:51:14 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/10/2021 6:19:12 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/2/2021 4:08:47 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/26/2021 5:07:46 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/26/2021 4:59:15 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/26/2021 4:55:50 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/17/2021 6:38:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/16/2021 5:19:38 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/16/2021 5:19:24 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/16/2021 4:52:26 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/16/2021 4:22:22 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/16/2021 4:16:38 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/12/2021 9:39:36 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 2/12/2021 8:06:59 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/4/2021 5:42:48 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/4/2021 5:40:52 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/3/2021 6:35:19 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/2/2021 5:06:29 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 2/2/2021 3:15:45 PM
Paulness   Tuesday, 11/17/20 09:25:22 AM
Re: None
Post # of 500 
NEWS -- Relmada Therapeutics to Participate in Upcoming Investor Conferences

NEW YORK, Nov. 17, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that Sergio Traversa, Chief Executive Officer of Relmada, will participate in the following upcoming virtual investor conferences:

Jefferies London Healthcare Conference

Date: Thursday, November 19, 2020
Time: 10:50 AM EST/3:50 PM GMT
Webcast: A live webcast of the fireside chat will be available by visiting the "Investors" section of the company's website: HTTP://www.relmada.com. A replay of the webcast will be available for 90 days following the conclusion of the live presentation broadcast.

Piper Sandler 32nd Annual Healthcare Conference

Management will participate in a fireside chat, which will be accessible beginning on November 23, 2020, via the "Investors" section of the company's website: HTTP://www.relmada.com. The link will remain active for 90 days thereafter.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a late-stage pharmaceutical company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Our experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada' s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission, and is entering late-stage studies as an adjunctive treatment for MDD in adults.

Investor Contact:
Tim McCarthy
LifeSci Advisors
212-915-2564
mailto://tim@lifesciadvisors.com

Media Inquiries:
FischTank PR
mailto://relmada@fischtankpr.com

View original content to download multimedia: http://www.prnewswire.com/news-releases/relmada-therapeutics-to-participate-in-upcoming-investor-conferences-301174575.html

SOURCE Relmada Therapeutics, Inc.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences